JP2008513469A5 - - Google Patents

Download PDF

Info

Publication number
JP2008513469A5
JP2008513469A5 JP2007532470A JP2007532470A JP2008513469A5 JP 2008513469 A5 JP2008513469 A5 JP 2008513469A5 JP 2007532470 A JP2007532470 A JP 2007532470A JP 2007532470 A JP2007532470 A JP 2007532470A JP 2008513469 A5 JP2008513469 A5 JP 2008513469A5
Authority
JP
Japan
Prior art keywords
toremifene
use according
dose
day
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007532470A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008513469A (ja
Filing date
Publication date
Priority claimed from US10/944,465 external-priority patent/US20050080143A1/en
Application filed filed Critical
Publication of JP2008513469A publication Critical patent/JP2008513469A/ja
Publication of JP2008513469A5 publication Critical patent/JP2008513469A5/ja
Pending legal-status Critical Current

Links

JP2007532470A 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療 Pending JP2008513469A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/944,465 US20050080143A1 (en) 2001-11-29 2004-09-20 Treatment of androgen-deprivation induced osteoporosis
PCT/US2005/032998 WO2006033979A1 (en) 2004-09-20 2005-09-19 Treatment of androgen - deprivation induced osteoporosis

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2008240566A Division JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Publications (2)

Publication Number Publication Date
JP2008513469A JP2008513469A (ja) 2008-05-01
JP2008513469A5 true JP2008513469A5 (enExample) 2010-04-22

Family

ID=36090335

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007532470A Pending JP2008513469A (ja) 2004-09-20 2005-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2008240566A Pending JP2009029823A (ja) 2004-09-20 2008-09-19 アンドロゲン除去によって生じる骨粗鬆症の治療

Country Status (12)

Country Link
US (1) US20050080143A1 (enExample)
EP (2) EP1935415A3 (enExample)
JP (2) JP2008513469A (enExample)
KR (1) KR20070059167A (enExample)
CN (2) CN101961327A (enExample)
AU (1) AU2005287113B2 (enExample)
BR (1) BRPI0515668A (enExample)
CA (1) CA2581159A1 (enExample)
EA (1) EA014309B1 (enExample)
IL (1) IL182091A0 (enExample)
MX (1) MX2007003272A (enExample)
WO (1) WO2006033979A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040092602A1 (en) * 1998-05-07 2004-05-13 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040186185A1 (en) * 1998-05-07 2004-09-23 Steiner Mitchell S. Method for treatment and chemoprevention of prostate cancer
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20060270641A1 (en) * 2005-05-31 2006-11-30 Steiner Mitchell S Method for chemoprevention of prostate cancer
CN116869944A (zh) * 2023-08-15 2023-10-13 重庆士立德医药科技有限公司 一种托瑞米芬组合物及其制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2464203A (en) 1943-05-21 1949-03-15 Boots Pure Drug Co Ltd Manufacture of dienoestrol
US2465505A (en) 1944-12-05 1949-03-29 Hoffmann La Roche Process for the manufacture of 3, 4-di-(p-hydroxy-phenyl)-hexadiene-2, 4
US2914562A (en) 1957-08-06 1959-11-24 Wm S Merrell Co Amine derivatives of triphenylethanol
GB8508404D0 (en) * 1985-03-30 1985-05-09 Baylor College Medicine Therapeutic compositions
US4897254A (en) * 1984-09-21 1990-01-30 The Dow Chemical Company Radioactive compositions for the treatment of calcific tumors
US4729999A (en) * 1984-10-12 1988-03-08 Bcm Technologies Antiestrogen therapy for symptoms of estrogen deficiency
FR2578113B1 (fr) * 1985-02-25 1988-04-15 Merlin Gerin Declencheur statique numerique a fonctions optionnelles pour un disjoncteur electrique
US4895715A (en) * 1988-04-14 1990-01-23 Schering Corporation Method of treating gynecomastia
DK0595796T3 (da) * 1989-07-07 2003-05-05 Endorech Inc Fremgangsmåde til behandling af androgen-relaterede sygdomme
US5153622A (en) * 1989-08-03 1992-10-06 Asahi Kogaku Kogyo Kabushiki Kaisha Pressure alarm for water-sealed camera
JPH06287885A (ja) * 1991-04-15 1994-10-11 Yamauchi Corp 脱水プレス用エンドレスベルト
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
TW303299B (enExample) * 1993-07-22 1997-04-21 Lilly Co Eli
TW403738B (en) * 1994-08-12 2000-09-01 Hoffmann La Roche Tricyclic pyrazole derivatives
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
US5552412A (en) * 1995-01-09 1996-09-03 Pfizer Inc 5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis
IL120262A (en) * 1996-02-28 2001-01-28 Pfizer Droloxifene and derivatives thereof for use in increasing serum testosterone levels
EP0891421A4 (en) * 1996-03-18 2001-07-25 Univ Pennsylvania BIOACTIVE SUBSTRATE MATERIAL FOR IMPROVED CELLULAR FIXATION AND FUNCTION
GB9712086D0 (en) * 1997-06-10 1997-08-13 Bp Chem Int Ltd Process for preparing polyketones
US6096764A (en) * 1997-08-21 2000-08-01 Eli Lilly And Company Methods for inhibiting detrimental side-effects due to GnRH of GnRH agonist administration
SI1003496T1 (en) * 1998-05-07 2005-10-31 The University Of Tennessee Research Corporation Medicament for treating prostate intraepithelial neoplasia
US6413533B1 (en) * 1998-05-07 2002-07-02 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6632447B1 (en) * 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) * 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
ATE315033T1 (de) * 1998-08-07 2006-02-15 Chiron Corp Subtituierte isoxazole derivate als estrogen rezeptor modulatore
US6165504A (en) * 1998-09-23 2000-12-26 Barr Laboratories, Inc. Methods for treating hot flashes and improving the quality of life of castrated prostatic cancer patients
US6258802B1 (en) * 1999-10-06 2001-07-10 Medical College Of Hampton Roads Corticoid therapy
EP1251855A1 (en) * 2000-01-28 2002-10-30 Endorecherche, Inc. Selective estrogen receptor modulators in combination with estrogens
US6855703B1 (en) * 2000-03-10 2005-02-15 Endeavor Pharmaceuticals Pharmaceutical compositions of conjugated estrogens and methods of analyzing mixtures containing estrogenic compounds
GB0012291D0 (en) * 2000-05-23 2000-07-12 Astrazeneca Ab Pharmaceutical combination
US7067557B2 (en) * 2000-05-26 2006-06-27 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
WO2001091744A1 (en) * 2000-05-26 2001-12-06 Harry Fisch Methods of treating androgen deficiency in men using selective antiestrogens
US20030114420A1 (en) * 2000-06-28 2003-06-19 Salvati Mark E. Fused cyclic modulators of nuclear hormone receptor function
HUP0303172A3 (en) * 2000-06-28 2006-05-29 Bristol Myers Squibb Co Selective androgen receptor modulators and methods for their identification, desing and use
AU2001271163A1 (en) * 2000-07-05 2002-01-14 Astrazeneca Ab Pharmaceutical combination of an anti-androgen and tamoxifen for providing an anti-androgenic effect and aromatase inhibition
EP1210951B1 (en) * 2000-11-30 2005-02-02 Pfizer Products Inc. Composition containing estrogen agonists/antagonists and testosterone for treating a decline in the level of the hormone testosterone
US6413633B1 (en) * 2001-04-18 2002-07-02 Francis Patrick McCullough Activated biregional fiber(s)
US6838584B2 (en) * 2001-05-10 2005-01-04 Merck & Co., Inc. Estrogen receptor modulators
DE02726901T1 (de) * 2001-05-17 2004-07-15 Immunex Corp., Seattle Therapeutische verwendung von rang-antagonisten
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
MXPA04005112A (es) * 2001-11-29 2005-04-29 Gtx Inc Prevencion y tratamiento de osteoporosis inducida por privacion de androgeno.
US20040152733A1 (en) * 2002-03-15 2004-08-05 Wallace Owen Brendan Duloxetine for treatment of hot flashes
MXPA05001705A (es) * 2002-08-14 2005-04-19 Pharmacia & Upjohn Co Llc Uso de reboxetina para el tratamiento de sofocos.
KR100748447B1 (ko) * 2002-08-23 2007-08-10 에이에스엠엘 네델란즈 비.브이. 리소그래피 투영장치 및 상기 장치에 사용하기 위한파티클 배리어
US7332525B2 (en) * 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
CA2523830A1 (en) * 2003-04-30 2004-11-11 Debiopharm S.A. Methods and compositions using gonadotropin hormone releasing hormone
US7048210B2 (en) * 2003-05-21 2006-05-23 Frank Clark Showerhead with grooved water release ducts
US20060019989A1 (en) * 2004-07-21 2006-01-26 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors and SERMs and methods of use thereof

Similar Documents

Publication Publication Date Title
FI3788047T3 (fi) Fgft-estäjän kiinteitä muotoja ja menetelmiä niiden valmistamiseksi
JP2023541432A5 (enExample)
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
JP2013541583A5 (enExample)
JP2011503063A5 (enExample)
NZ595189A (en) Combination therapy with thiocolchicine derivatives
JP2016185995A5 (enExample)
JP2011068653A5 (enExample)
HK1221646A1 (zh) 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途
JP2017506624A5 (enExample)
JP2015515985A5 (enExample)
FI3000467T3 (fi) Rintasyöpähoitokuuri, jossa käytetään neratinibia
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
ME02474B (me) Terapijski režimi
JP2016507500A5 (enExample)
JP2015508765A5 (enExample)
JP2005519936A5 (enExample)
CN102028689B (zh) 一种治疗急性淋巴白血病的复方药物组合物
RU2018119085A (ru) Схема введения ингибитора фосфатидилинозитол-3-киназы
RU2016116915A (ru) Комбинация
CO2018009543A2 (es) Composición farmacéutica de liberación prolongada que comprende cisteamina o sal de la misma
HRP20220701T1 (hr) Spojeni benzazepini za liječenje touretteova sindroma
JP2012517459A5 (enExample)
TN2016000179A1 (en) Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor.
RU2015128024A (ru) Фармацевтическая композиция на основе хлорпрокаина для повторного интратекального введения